Cargando…
Can Epstein–Barr virus‐deoxyribonucleic acid load after induction chemotherapy combined with American Joint Committee on Cancer stage determine the chemotherapy intensity of locally advanced nasopharyngeal carcinoma?
BACKGROUND: Induction chemotherapy (IC) comprising docetaxel, cisplatin, and fluorouracil (TPF), combined with concurrent chemoradiotherapy (CCRT) effectively improves the survival rate of locally advanced nasopharyngeal carcinoma (LA‐NPC). Selecting patients whose risk of tumor recurrence and metas...
Autores principales: | Zhang, Qun, Peng, Zhen‐Wei, Gu, Zhuo‐Sheng, Wang, Yan, He, Fang, Zhao, Wen‐Bin, Luo, Wei, Mei, Yong‐Yu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9844613/ https://www.ncbi.nlm.nih.gov/pubmed/35674137 http://dx.doi.org/10.1002/cam4.4899 |
Ejemplares similares
-
Individualized induction chemotherapy by pre-treatment plasma Epstein-Barr viral DNA in advanced nasopharyngeal carcinoma
por: Zhang, Jian, et al.
Publicado: (2018) -
Magnetic Resonance Imaging-Detected Tumor Residue after Intensity-Modulated Radiation Therapy and its Association with Post-Radiation Plasma Epstein-Barr Virus Deoxyribonucleic Acid in Nasopharyngeal Carcinoma
por: Lv, Jia-Wei, et al.
Publicado: (2017) -
Prognostic effect of residual plasma Epstein–Barr viral DNA after induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma
por: Zheng, Hua, et al.
Publicado: (2023) -
Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients based on plasma Epstein–Barr virus DNA level after induction chemotherapy
por: Liu, Sai-Lan, et al.
Publicado: (2020) -
Radiotherapy Alone Versus Concurrent or Adjuvant Chemoradiotherapy for Nasopharyngeal Carcinoma Patients with Negative Epstein–Barr Virus DNA after Induction Chemotherapy
por: Kong, Fangfang, et al.
Publicado: (2023)